Diabetes Mellitus Type 2 in Obese Clinical Trial
Official title:
The GATE Trial: Endoscopic Sutured Gastroplasty in Type 2 Diabetic, Obese Patients Using the Endomina Device - a Randomized Controlled Trial
Rationale: Diabetes mellitus is a chronic disease that is often associated with long-term macrovascular and microvascular complications and decreased life expectancy. Approximately 70% of patients with type 2 diabetes mellitus (DM2) are overweight or obese. Weight loss benefits several aspects of DM2, such as improved glycemic control, increased insulin sensitivity and reduced fasting insulin. Interventions for weight loss in patients with DM2 include diet, exercise, but also pharmacotherapy and bariatric surgery. Bariatric surgery is indicated at a body mass index (BMI) > 35 kg/m², in combination with other comorbidities. It is associated with better glycemic control and more weight reduction, compared to intensive medical treatment alone. For patients with not adequately controlled DM2 who are not eligible for surgery (i.e., BMI of < 35 kg/m²), there is a therapeutic gap, which could be filled by one of the currently available endoscopic therapies aiming to reduce weight. One of these therapies is endoscopic sutured gastroplasty (ESG), performed with the endomina device (EndoTools Therapeutics S.A.). There is however a paucity of data showing the effect of ESG on metabolic comorbidities including DM2. We hypothesize that ESG with the endomina device will improve glycemic control in patients with DM2 and obesity. Objective: To evaluate the efficacy of ESG with the endomina device on glycemic control, in obese insulin treated type 2 diabetic patients. Study design: This is a prospective, randomized controlled trial. Study population: 58 subjects (29 in each group) with a BMI between 30 and 40 kg/m² and DM2, treated with insulin therapy. Intervention (if applicable): The intervention group will receive ESG performed with the endomina device. The control group will receive standard diabetic care. Main study parameters/endpoints: The primary endpoint is the proportion of patients with a clinically relevant reduction of insulin dose. Secondary endpoints include among others reduction in HbA1c, remission of diabetes, weight loss, quality of life and (serious) adverse events. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: An ESG with the endomina device is known to have only minor adverse events (transient abdominal cramps, nausea, vomiting), and a serious adverse event rate of <1% (no surgical intervention needed, no mortality).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02668328 -
Cochlear-Vestibular Ganglion (CVG) in Newly Diagnosed Type 2 Diabetes Patients
|
N/A | |
| Completed |
NCT04314427 -
Early Glycaemic Control in Type 2 Diabetes Patients After Bariatric Surgery; ECODABS
|
||
| Recruiting |
NCT05942079 -
"The Effect of Reiki on Metabolic Parameters in Obese Type 2 Diabetes Patients''
|
||
| Not yet recruiting |
NCT06333132 -
Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)
|
N/A | |
| Active, not recruiting |
NCT05579561 -
Vegetarian Ketogenic Diet VS Omnivore Ketogenic Diet - Protocol of a Keto-vege Diet for Remission of Type 2 Diabetes
|
N/A | |
| Completed |
NCT02938026 -
Changes of Diet, Physical Activity and Sleep Pattern and Their Effects on Glycemic and Weight Control in Hong Kong Chinese Obese Patients With Type 2 Diabetes After Bariatric Surgery Compared to Telephone Intensive Lifestyle Counselling
|
N/A | |
| Recruiting |
NCT05887271 -
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
|
Phase 2/Phase 3 | |
| Completed |
NCT02680873 -
Efficacy of SASI Bypass for Type-2 Diabetic Obese Patients
|
N/A | |
| Completed |
NCT01364350 -
TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study
|
||
| Completed |
NCT02784275 -
A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT01874366 -
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187
|
Phase 1 | |
| Recruiting |
NCT03821636 -
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
|
N/A | |
| Recruiting |
NCT03904901 -
Influence of Probiotics in Diabetic Cardiopathies With Excessive Weight
|
N/A | |
| Active, not recruiting |
NCT01989988 -
DMBSS-A Randomized Trial of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM
|
N/A | |
| Completed |
NCT02122874 -
Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients
|
Phase 3 | |
| Completed |
NCT03394157 -
Randomized Comparative Study of Sleeve Gastrectomy Versus MGB and SASI Bypass , Randomized Study
|
N/A | |
| Recruiting |
NCT04227769 -
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
|
Phase 2 | |
| Active, not recruiting |
NCT05755321 -
From Skin Fibroblasts to Neural Stem Cells to Investigate in Vitro the Impact of Diabetes on Adult Neurogenesis
|
||
| Completed |
NCT04957589 -
VLCD & Adjuvant Exercise Effect in Overweight Diabetic Men
|
N/A | |
| Recruiting |
NCT05801614 -
Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction
|
N/A |